- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00608101
Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus
December 10, 2014 updated by: Steve Davis, Vanderbilt University
Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 1
The purpose of this study is to determine what corticosteroid receptor (and the dose of) is responsible for cortisol inducing hypoglycemia associated autonomic dysfunction in Type 1 DM.
Specifically, we aim to determine whether stimulating the type 1 corticosteroid receptor (via fludrocortisone), the type 2 corticosteroid receptor (via dexamethasone), or both causes hypoglycemia associated autonomic dysfunction in Type 1 DM.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 16 (8 males, 8 females) Type 1 diabetic patients aged 18-45 yr.
- HbA1c > 7.0%
- Had diabetes for 2-15 years
- No clinical evidence of diabetic tissue complications
- 16 (8 males, 8 females) Healthy volunteers aged 18-45 yrs.
- Body mass index < 27kg · m-2
Exclusion Criteria:
- Prior or current history of poor health
- Abnormal results following blood and physical examination
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Day 1 hyperinsulinemic euglycemic clamps with either 0.2 mg fludrocortisone, 0.75 mg Dexamethasone, or both given orally before each morning and afternoon clamp.
Day 2 hyperinsulinemic hypoglycemic glucose clamp.
|
Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
|
EXPERIMENTAL: 2
Fludrocortisone will be administered in doses of 0.05mg, 0.1mg and 0.2 mg form at the start of each clamp period on day 1.
Dexamethasone will be administered orally in the doses of 0.18 mg, 0.375mg and 0.75mg doses.
The combination of the 0.05mg fludrocortisone and 0.18mg dexamethasone and 0.1mg of fludrocortisone and 0.375 mg doses will be administered at the start of each day 1 clamp period.
Day 2 90 minutes of moderate exercise.
|
Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
catecholamines
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (ACTUAL)
September 1, 2010
Study Completion (ACTUAL)
September 1, 2010
Study Registration Dates
First Submitted
January 23, 2008
First Submitted That Met QC Criteria
February 5, 2008
First Posted (ESTIMATE)
February 6, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
December 11, 2014
Last Update Submitted That Met QC Criteria
December 10, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Nervous System Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Diabetes Mellitus, Type 1
- Hypoglycemia
- Pure Autonomic Failure
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
- Fludrocortisone
Other Study ID Numbers
- IRB #040907-HAAF in T1DM, Q1
- R01DK069803-03 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Fludrocortisone
-
Rennes University HospitalCompleted
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedCorticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury (Corti-TC)Pneumonia | Trauma | Traumatic Brain Injury | Adrenal InsufficiencyFrance
-
University of CalgaryCanadian Institutes of Health Research (CIHR)CompletedSyncope, Vasovagal, Neurally-MediatedUnited States, Canada
-
The George InstituteCompletedSeptic Shock | Critically IllAustralia
-
Assistance Publique - Hôpitaux de ParisCompletedPartial Mineralocorticoid DeficiencyFrance
-
Oregon Health and Science UniversityTerminated
-
Rennes University HospitalTerminated
-
H.A.C. PHARMARecruitingNeurogenic Orthostatic HypotensionFrance
-
Leiden University Medical CenterCompleted